相似文献
1
Role of Chromatin and Epigenetic Dysregulation in Prostate Cancer: From Development to Progression and Therapeutic Response.
Cancers (Basel). 2023 Nov 29;15(23):5638. doi: 10.3390/cancers15235638.
2
Crosstalk between epigenetics and tumor promoting androgen signaling in prostate cancer.
Vitam Horm. 2023;122:253-282. doi: 10.1016/bs.vh.2022.11.007. Epub 2022 Dec 29.
3
Epigenetic regulation of pluripotency inducer genes NANOG and SOX2 in human prostate cancer.
Prog Mol Biol Transl Sci. 2023;197:241-260. doi: 10.1016/bs.pmbts.2023.01.010. Epub 2023 Mar 2.
4
Epigenetic Regulation in Prostate Cancer Progression.
Curr Mol Biol Rep. 2018;4(2):101-115. doi: 10.1007/s40610-018-0095-9. Epub 2018 Apr 18.
5
Can epigenetic and inflammatory biomarkers identify clinically aggressive prostate cancer?
World J Clin Oncol. 2020 Feb 24;11(2):43-52. doi: 10.5306/wjco.v11.i2.43.
6
Epigenetic reprogramming during prostate cancer progression: A perspective from development.
Semin Cancer Biol. 2022 Aug;83:136-151. doi: 10.1016/j.semcancer.2021.01.009. Epub 2021 Feb 2.
7
The phytochemical 3,3'-diindolylmethane decreases expression of AR-controlled DNA damage repair genes through repressive chromatin modifications and is associated with DNA damage in prostate cancer cells.
J Nutr Biochem. 2017 Sep;47:113-119. doi: 10.1016/j.jnutbio.2017.05.005. Epub 2017 May 25.
8
Epigenetic and Epitranscriptomic Control in Prostate Cancer.
Genes (Basel). 2022 Feb 18;13(2):378. doi: 10.3390/genes13020378.
9
Epigenetics-based diagnostic and therapeutic strategies: shifting the paradigm in prostate cancer.
Epigenomics. 2023 Jan;15(2):75-87. doi: 10.2217/epi-2023-0045. Epub 2023 Mar 28.
10
Epigenetics in prostate cancer: biologic and clinical relevance.
Eur Urol. 2011 Oct;60(4):753-66. doi: 10.1016/j.eururo.2011.06.035. Epub 2011 Jun 22.
引用本文的文献
1
Emerging biomarkers for non-invasive diagnosis and treatment of cancer: a systematic review.
Front Oncol. 2024 Jul 26;14:1405267. doi: 10.3389/fonc.2024.1405267. eCollection 2024.
本文引用的文献
1
Chromatin and Epigenetic Dysregulation of Prostate Cancer Development, Progression, and Therapeutic Response.
Cancers (Basel). 2021 Jul 2;13(13):3325. doi: 10.3390/cancers13133325.
2
Chromatin openness requires continuous SWI/SNF activity.
Nat Genet. 2021 Mar;53(3):263-264. doi: 10.1038/s41588-021-00781-7.
3
Loss and revival of androgen receptor signaling in advanced prostate cancer.
Oncogene. 2021 Feb;40(7):1205-1216. doi: 10.1038/s41388-020-01598-0. Epub 2021 Jan 8.
4
Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity.
Nat Commun. 2020 Nov 3;11(1):5549. doi: 10.1038/s41467-020-19328-1.
5
m6A methyltransferase METTL3 promotes the progression of prostate cancer via m6A-modified LEF1.
Eur Rev Med Pharmacol Sci. 2020 Apr;24(7):3565-3571. doi: 10.26355/eurrev_202004_20817.
6
A high-resolution 3D epigenomic map reveals insights into the creation of the prostate cancer transcriptome.
Nat Commun. 2019 Sep 12;10(1):4154. doi: 10.1038/s41467-019-12079-8.
7
The Metabolic Landscape of Prostate Cancer.
Eur Urol Oncol. 2019 Feb;2(1):28-36. doi: 10.1016/j.euo.2018.06.010. Epub 2018 Jul 19.
8
Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer.
Cell Rep. 2017 Jun 6;19(10):2045-2059. doi: 10.1016/j.celrep.2017.05.049.
9
GSTP1 Methylation and Protein Expression in Prostate Cancer: Diagnostic Implications.
Dis Markers. 2016;2016:4358292. doi: 10.1155/2016/4358292. Epub 2016 Aug 10.
10
One-Carbon Metabolism in Prostate Cancer: The Role of Androgen Signaling.
Int J Mol Sci. 2016 Jul 27;17(8):1208. doi: 10.3390/ijms17081208.
Zotero 插件